| Literature DB >> 34699640 |
Yutong Zou1, Zhijuan Liu2, Honglei Li1, Li'an Hou1, Jinrong Pang2, Xiaoxing Liu3, Liping Tian4, Qi Zhang1, Chaochao Ma1, Songlin Yu1, Danchen Wang1, Xiuzhi Guo1, Xinqi Cheng1, Hongyan Yang2, Ling Qiu1,5.
Abstract
AIM: To measure and evaluate the distribution and possible contributing factors of seven bone metabolism-associated biomarkers in Tibet, a plateau province of China.Entities:
Keywords: Tibetan; biochemical markers; bone metabolism; plateau
Mesh:
Substances:
Year: 2021 PMID: 34699640 PMCID: PMC8649332 DOI: 10.1002/jcla.24068
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Participant characteristics based on altitude and sex
| Variables | Group A | Group B | Group C | |||
|---|---|---|---|---|---|---|
| Male ( | Female ( | Male ( | Female ( | Male ( | Female ( | |
| Age (y) | 36 ± 10 | 36 ± 10 | 40 ± 12 | 42 ± 12 | 42 ± 11 | 41 ± 12 |
| BMI (kg/m2) | 23.6 ± 3.5 | 22.6 ± 4.0 | 24.8 ± 3.8 | 24.0 ± 3.9 | 26.0 ± 3.6 | 24.4 ± 4.1 |
| SBP (mmHg) | 114 ± 17 | 107 ± 18 | 122 ± 17 | 117 ± 16 | 124 ± 18 | 121 ± 21 |
| DBP (mmHg) | 74 ± 15 | 72 ± 13 | 85 ± 14 | 80 ± 12 | 83 ± 14 | 77 ± 14 |
| Alb (g/L) | 49.2 ± 3.1 | 47.1 ± 3.2 | 50.0 ± 3.3 | 47.8 ± 3.1 | 46.9 ± 2.7 | 46.3 ± 2.6 |
| ALT (U/L) | 36 (25,57) | 20 (14,29) | 31 (21,50) | 18 (13,27) | 32 (22,49) | 20 (15,29) |
| TG (mmol/) | 1.01 (0.71,1.65) | 0.70 (0.55,1.02) | 1.12 (0.85,1.50) | 0.86 (0.60,1.20) | 1.23 (0.92,1.72) | 0.86 (0.63,1.19) |
| TC (mmol/L) | 4.74 ± 1.02 | 4.34 ± 0.76 | 4.95 ± 0.97 | 4.72 ± 0.91 | 4.79 ± 0.85 | 4.63 ± 0.93 |
| Glucose (mmol/L) | 4.99 ± 0.86 | 4.71 ± 0.53 | 4.56 ± 1.10 | 4.39 ± 0.93 | 4.88 ± 1.11 | 4.66 ± 0.85 |
| Urea (mg/dL) | 4.68 ± 1.25 | 4.34 ± 1.25 | 4.69 ± 1.33 | 4.31 ± 1.04 | 4.66 ± 1.29 | 4.25 ± 1.14 |
Age, BMI, SBP, DBP, and the levels of Alb, TC, glucose, and urea are presented as mean ± SD; ALT and TG are presented as medians (25th and 75th percentiles).
Abbreviations: Alb, Albumin; ALT, Alanine transaminase; BMI, Body mass index; DBP, Diastolic blood pressure; SBP, Systolic blood pressure; TC, Total cholesterol; TG, Triglyceride.
Standard partial correlation coefficients from multiple regression analysis
| Variables | R‐value | Group B | Group C | Sex | 30–39 years | 40–49 years | 50–64 years | BMI | SBP |
|---|---|---|---|---|---|---|---|---|---|
| Serum calcium | 0.369 |
|
|
|
|
| −0.064 |
| 0.009 |
| Serum phosphorus | 0.405 |
|
|
|
|
| −0.014 | −0.056 |
|
| ALP | 0.275 | 0.001 | −0.060 |
| −0.032 | −0.042 |
|
| 0.062 |
| 25OHD | 0.554 | −0.058 |
|
| 0.016 | −0.023 |
|
| 0.042 |
| PINP | 0.381 |
| 0.026 |
|
|
|
| −0.067 | −0.015 |
| β‐CTX | 0.413 |
|
|
|
|
| −0.062 |
| 0.015 |
| PTH | 0.463 |
|
|
| 0.027 | 0.016 | −0.040 |
| 0.020 |
Abbreviations: 25OHD, 25 Hydroxyvitamin D; ALP, Serum alkaline phosphatase; BMI, Body mass index; PINP, Type I collagen amino terminal elongation peptide; PTH, Parathyroid hormone; SBP, Systolic blood pressure; β‐CTX, β‐collagen degradation products.
* p < 0.05.
Distribution of bone metabolism‐associated biomarkers based on altitude and sex
| Variables | Group A | Group B | Group C | Total | ||||
|---|---|---|---|---|---|---|---|---|
| Male ( | Female ( | Male ( | Female ( | Male ( | Female ( | Male ( | Female ( | |
| Calcium (mmol/L) | 2.45 ± 0.12* | 2.38 ± 0.13 | 2.50 ± 0.13* | 2.45 ± 0.14 | 2.36 ± 0.09 | 2.39 ± 0.11 | 2.45 ± 0.13# | 2.41 ± 0.13# |
| Phosphorus (mmol/L) | 1.11 ± 0.13* | 1.19 ± 0.19 | 1.19 ± 0.17* | 1.22 ± 0.17 | 1.02 ± 0.15* | 1.17 ± 0.16 | 1.13 ± 0.17# | 1.20 ± 0.17# |
| ALP (U/L) | 117.8 ± 33.2* | 92.1 ± 26.9 | 112.9 ± 29.5* | 102.5 ± 32.2 | 107.2 ± 28.6 | 99.5 ± 28.6 | 112.7 ± 30.4# | 99.2 ± 30.0# |
| 25OHD (ng/ml) | 25.6 ± 9.6* | 16.7 ± 6.4 | 24.7 ± 7.8* | 15.0 ± 5.9 | 21.5 ± 6.3* | 14.2 ± 5.4 | 24.0 ± 8.0# | 15.0 ± 5.9# |
| PINP (ng/ml) | 70.9 (34.2, 166.5)* | 60.9 (21.7, 174.0) | 68.8 (28.5, 158.8)* | 62.2 (22.0, 158.0) | 74.0 (29.70, 188.6) | 66.5 (29.9, 161.8) | 69.3 (31.0, 166.5)# | 62.1 (22.8, 159.1) |
| β‐CTX (ng/ml) | 0.61 (0.24, 1.23)* | 0.50 (0.17, 1.20) | 0.46 (0.22, 1.02)* | 0.35 (0.15, 0.95) | 0.50 (0.18, 1.12) | 0.44 (0.15, 1.00) | 0.50 (0.22, 1.16)# | 0.40 (0.16, 1.03)# |
| PTH (pg/ml) | 33.9 (18.2, 73.8)* | 38.0 (19.5, 60.8) | 38.1 (18.3, 75.5)* | 44.1 (21.9, 81.3) | 49.4 (24.7, 93.7)* | 54.1 (28.2, 105.6) | 40.4 (20.5, 83.9)# | 45.8 (22.2, 90.7)# |
Abbreviations: ALP, Serum alkaline phosphatase; 25OHD, 25 Hydroxyvitamin D; PINP, type I collagen amino terminal elongation peptide; β‐CTX, β‐collagen degradation products; PTH, parathyroid hormone. Calcium, phosphorus, ALP, and 25OHD levels are presented as mean ± SD; PINP, β‐CTX, and PTH levels are presented as medians (2.5th and 97.5th percentiles).
*Meant significant difference between sex in different altitude groups
#Meant significant difference among altitude groups in different sex.
FIGURE 1Distribution of bone metabolism‐associated biomarkers with age. ALP, serum alkaline phosphatase; 25OHD, 25 Hydroxyvitamin D; PINP, type I collagen amino terminal elongation peptide; β‐CTX, β‐collagen degradation products; PTH, parathyroid hormone
FIGURE 2Prevalence of abnormal bone metabolism‐associated biomarkers in Tibetan adults. ALP, serum alkaline phosphatase; PINP, type I collagen amino terminal elongation peptide; β‐CTX, β‐collagen degradation products; PTH, parathyroid hormone. (A) indicates that the levels of these biomarkers were lower than the lower limit of RIs; (B) indicates that the levels were higher than the upper limit of the RIs